Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

David R. Walt

Quanterix Corporation

QuidelOrtho provides diagnostic solutions and products aimed at enhancing healthcare through testing capabilities in both at-home and clinical settings. Self-described as offering solutions across the healthcare continuum.

QuidelOrtho

MSD is involved in research and development in various areas including antibiotics, vaccines, HIV, diabetes, and oncology. The company is self-described as focused on health literacy and responsible corporate practices.

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of  health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Alzheimer's Drug Discovery Foundation

bioMerieux

In-Q-Tel

ARCH Venture Partners

T. Rowe Price

Cormorant Asset Management

Hercules Capital

Trinitas Capital

Tufts University

ARCH Overage Fund

Bain Capital Ventures

Quanterix

The inaccessibility of inexpensive and noninvasive Alzheimer’s diagnostics has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting quality of life, medical autonomy, and general wellbeing.

Currently, clinicians diagnose AD using a combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD. Despite their effectiveness, they are often invasive and costly, making them unsuitable for most primary and secondary care settings, but blood-based biomarkers may offer a new path. There is substantial evidence supporting the utility of blood biomarkers for AD diagnosis, particularly diagnosing early-stage AD, prior to cognitive symptom presentation. https://bit.ly/3TcfGT6

#AlzheimersDisease #Biomarkers #CSF

Clinicians use various biomarkers to diagnose, track, and treat disease, and new biomarkers or improving the sensitivity of existing biomarkers could fulfill unmet clinical needs and improve patient outcomes. Blood-based markers like NfL, p-Tau 181, p-Tau 217, and GFAP are already playing a critical role in advancing patient care for disorders like Alzheimer’s and Parkinson’s. https://bit.ly/3RilsA9

The Scientist #Biomarkers #Alzheimers #BloodTest

A team from Wyss Institute at Harvard University, Massachusetts Institute of Technology, and Brigham and Women's Hospital in Boston demonstrated the use of microneedles and ultra-sensitive Simoa measurements to monitor protein biomarkers in responses to a combination immunotherapy against melanoma.

Learn more about the study and Simoa’s pivotal role: https://bit.ly/44rlF8I

Quanterix invites you to delve into the forefront of neurology laboratory medicine. Our recent Nature Portfolio webinar, featuring Dr. Cheryl Wellington from the The University of British Columbia, explores the transformative role of ultrasensitive immunoassays in researching blood biomarkers for neurological indications. From traumatic brain injuries to neurodegenerative diseases, this webinar is a valuable resource for those passionate about advancing neurological research. Access the recording here: https://bit.ly/47IKRcK 🧠 

#NeurologyLabMedicine #WebinarRecording

Metric
Company Name	Quanterix Corporation	QuidelOrtho	MSD
Symbol	QTRX
MSH ID	COM:QUANTERIX	COM:QUIDEL	PT:MSD
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Devices	Medical Devices and Diagnostics	Pharmaceuticals
Country	US	US	PT
Stage
Employee Count	441
Website	quanterix.com	quidel.com	msd.pt
LinkedIn	quanterix
Founders

Metric
Market Cap	508.23M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	121.14M
Revenue (LTM)
Revenue (NTM)
Gross Profit	69.42M
EBITDA	-38.25M
Operating Income	-49.70M
Net Income	-32.33M
EPS	-0.86
Diluted EPS	-0.86
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55
Operating Profit Margin	-0.42
EBITDA Margin	-0.32
Net Profit Margin	-0.27
Return on Equity	-0.09
Return on Assets	-0.08
Return on Capital Employed	-0.13

COM:QUANTERIX

Quanterix Corporation

Last Close

11.72

22/11 21:00

Market Cap

508.23M

Beta: -

Volume Today

256.54K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-22.85
P/B Ratio	2.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.43
EV Multiple	-8.82

Metric
Days Sales Outstanding	76.07
Days Payables Outstanding	34.80
Days Inventory Outstanding	176.13
Operating Cycle	266.18
Cash Conversion Cycle	231.93
Asset Turnover	0.31

Metric
Operating Cash Flow	-18.90M
Free Cash Flow	-22.69M
Cash Flow to Debt	-0.46
Operating Cash Flow/Sales	-0.16
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	174.42M
Accounts Receivable	-6.70M
Inventory	22.36M
Goodwill
Debt to Capitalization	0.11
Debt to Assets	0.10
Current Ratio	10.84
Quick Ratio	10.57

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.14
R&D to Revenue	0.20
SG&A to Revenue	0.42